Elevation of E-selectin concentrations may correlate with potential endothelial dysfunction in individuals with hypopituitarism during therapy with growth hormone.

Plain-language guide to PMID 17311545 (2007): controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 patients.

Key Facts

PMID: 17311545
Journal: Current neurovascular research
Year: 2007
Study type: Controlled Clinical Trial
Authors: Gómez JM et al. (7 authors)
DOI: 10.2174/156720207779940662

What This Study Did, in Plain Language

What Was Tested

This controlled clinical trial looks at Exogenous HGH, sermorelin & older GHRPs (why they're passed over).

The objective of this study was the assessment of fibrinolytic markers, soluble adhesion molecules, inflammatory cytokines and endothelial function in hypopituitary adults with GH deficiency and with GH replacement therapy.

Why It Was Studied

All subjects, patients and controls, were life-long non-smokers, normotensive and non-diabetic.

The following variables were recorded: anthropometrical and body composition variables, serum concentrations of glucose, insulin and C-peptide; thrombin anti-thrombin fragments and fibrin degradation product D-dimer that were determined by an enzyme-linked-immunosorbent assay (ELISA); IGF-I by radioimmunoassay; C-reactive protein by highly sensitive immunonephelometry; E-selectine, P-selectine, soluble intercellular cell adhesion molecule-1, soluble vascular cell adhesion molecule-1, interleukin-6 and monocyte chemoattractant protein-1 by ELISA.

Who Took Part

The study group was 20 patients.

PubMed indexes the participants as adults and middle-aged adults, both men and women.

The assessment of endothelial function in vivo was measured by Doppler.

What Was Measured

Topics PubMed links to this paper include Biomarkers, C-Reactive Protein, Chemokine CCL2, E-Selectin, Endothelium, Vascular, Fibrinolysis and Human Growth Hormone.

What This Means in Plain Language

This is a controlled clinical trial of Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in 20 patients.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The publication is from 2007 (Current neurovascular research), a journal based in United Arab Emirates.

More context: the Exogenous HGH, sermorelin & older GHRPs (why they're passed over) compound page, all human trials.

Our Notes on the Compound

Exogenous HGH, sermorelin & older GHRPs (why they're passed over): Constant levels suppress the body's own GHRH, raise somatostatin and dull pituitary response.

Exogenous HGH, sermorelin & older GHRPs (why they're passed over) in the library

Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.